APA (7th ed.) Citation

RC, N., Y, J., CC, L., YF, L., YB, C., XW, S., . . . SQ, Y. (2026). Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 44(20), 1869. https://doi.org/10.1200/JCO-25-02842

Chicago Style (17th ed.) Citation

RC, Nie, et al. "Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 44, no. 20 (2026): 1869. https://doi.org/10.1200/JCO-25-02842.

MLA (9th ed.) Citation

RC, Nie, et al. "Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 44, no. 20, 2026, p. 1869, https://doi.org/10.1200/JCO-25-02842.